Contract research organisation QPS has installed version 5.7.8 of Debra, Lablogic's LIMS for absorption, distribution, metabolism and excretion studies (ADME) at its Newark, Delaware facility.
'Studies determining ADME patterns in laboratory animals and humans are an integral part of our drug metabolism and pharmacokinetic services and, as a quality initiative, we have been actively integrating radio-labelled mass balance/excretion and tissue distribution by Quantitative Whole-Body Autoradiography under one study protocol,' said Ben Chien, QPS chairman, president and chief executive officer.
'This allows us to start on the companion metabolite profiling and identification studies in a shorter time frame,' he added.
'Increasingly, many pharmaceutical customers are using turnkey ADME solution providers such as QPS - not just for their in vivo studies, but also for radiochromatography on their samples and the ensuing determination of key metabolites,' said Huw Loaring, systems director at Lablogic.
'We are excited by the new tools coming early next year to allow CROs to share data back to their sponsors, which will allow them to understand the human biotransformation pathways of their drug candidates at a very early stage of development,' he said.
'The latter is extremely important, not only in terms of identifying MIST-triggering metabolites but also because it supports bio-waiver applications,' he added.
